Leadership Team

A highly experienced team with a strong track record of performance

The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics, a clinical-stage oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million.

Board

Dr Malcolm McColl
CEO, Co-Founder and Acting Chairman
Prof. Darren Shafren
CSO and Co-Founder
Dr Leonard Post
Non-Executive Director
Mr Robert Routley
Non-Executive Director
Dr Jeannie Joughin
Non-Executive Director

Management Team

Mr Robert Vickery
Chief Financial Officer
Dr Jennifer Rosenthal
Director Quality and Regulatory Affairs
Dr Min Yuan Quah
Director Discovery & Pre-clinical Research
Ms Bronwyn Davies
Director CMC
Dr Susanne Johansson
Director Quality Management
Dr Yvonne Wong
Director Manufacturing Science
Dr Roberta Karpathy
Director Clinical Science
Dr Naomi Croll
Consultant Project Manager - Clinical Operations
In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories
ImmVirX raising $25m led by renowned healthcare VC OneVentures
Company Announcements
June 5, 2023
ImmVirX enters the clinic with next generation oncolytic virus
Company Announcements
April 11, 2023

Join Our Mailing List

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect

About Us
Our Technology

A clinical stage company developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations

Company
© 2020 ImmVirX Pty Ltd • Site by Alex Shafren & Noise